LitCovid-sample-Enju  

PMC:7205724 / 18627-19106 JSONTXT 16 Projects

Annnotations TAB TSV DIC JSON TextAE Lectin_function

Id Subject Object Predicate Lexical cue
T18993 0-3 DT denotes The
T21718 4-9 NN denotes study
T64168 10-11 -LRB- denotes [
T66430 11-13 CD denotes 23
T95152 13-14 -RRB- denotes ]
T31198 15-23 VBD denotes included
T55004 24-27 CD denotes ten
T65830 28-36 NNS denotes patients
T56952 37-41 IN denotes with
T98815 42-50 NN denotes COVID-19
T69048 51-54 WP denotes who
T75376 55-67 VBD denotes demonstrated
T59786 68-77 VBG denotes worsening
T24326 78-86 NNS denotes symptoms
T13700 86-87 -COMMA- denotes ,
T79561 88-92 FW denotes e.g.
T83448 92-93 -COMMA- denotes ,
T77014 94-103 VBD denotes decreased
T40148 104-114 NN denotes lymphocyte
T31095 115-120 NN denotes count
T13833 121-124 CC denotes and
T80531 125-134 VBD denotes decreased
T26060 135-144 NN denotes PaO2/FIO2
T3471 145-150 NN denotes ratio
T11859 151-154 CC denotes and
T6067 155-161 NN denotes oxygen
T65980 162-172 NN denotes saturation
T58632 172-173 -COMMA- denotes ,
T52543 174-183 VBG denotes following
T84435 184-193 NN denotes treatment
T44273 194-198 IN denotes with
T99668 199-200 DT denotes a
T65524 201-211 JJ denotes short-term
T66169 212-225 JJ denotes moderate-dose
T25963 226-240 NN denotes corticosteroid
T54040 241-242 -LRB- denotes (
T15835 242-260 NN denotes methylprednisolone
T75851 261-268 NN denotes 80 mg/d
T55858 268-269 -RRB- denotes )
T6426 270-274 CC denotes plus
T60445 275-289 NN denotes immunoglobulin
T91733 290-291 -LRB- denotes (
T10263 291-297 CD denotes 10 g/d
T89099 297-298 -RRB- denotes )
T32422 300-305 IN denotes After
T38661 306-315 VBG denotes switching
T47400 316-318 TO denotes to
T27854 319-322 DT denotes the
T88178 323-329 JJ denotes double
T22917 330-334 NN denotes dose
T27562 335-337 IN denotes of
T69861 338-347 NN denotes 1600 mg/d
T26688 348-366 NN denotes methylprednisolone
T91618 367-371 CC denotes plus
T63033 372-378 NN denotes 20 g/d
T82872 379-393 NN denotes immunoglobulin
T48110 393-394 -COMMA- denotes ,
T64285 395-398 DT denotes all
T67888 399-401 IN denotes of
T16788 402-405 DT denotes the
T67776 406-414 NNS denotes patients
T6163 415-423 VBN denotes improved
T27596 424-426 IN denotes in
T10929 427-430 DT denotes the
T87507 431-439 JJ denotes clinical
T10805 439-440 -COMMA- denotes ,
T49266 441-451 NN denotes laboratory
T95692 451-452 -COMMA- denotes ,
T51590 453-456 CC denotes and
T63732 457-469 JJ denotes paraclinical
T58895 470-478 NNS denotes outcomes
R14407 T21718 T64168 arg1Of study,[
R14909 T58895 T10929 arg1Of outcomes,the
R16749 T10805 T51590 arg1Of ",",and
R16771 T13833 T13700 arg2Of and,","
R17219 T21718 T77014 arg1Of study,decreased
R17542 T6163 T48110 arg1Of improved,","
R1770 T77014 T13833 arg1Of decreased,and
R18986 T65980 T6067 arg1Of saturation,oxygen
R19341 T3471 T26060 arg1Of ratio,PaO2/FIO2
R22057 T31095 T77014 arg2Of count,decreased
R22662 T84435 T44273 arg1Of treatment,with
R25333 T65830 T56952 arg1Of patients,with
R2563 T82872 T63033 arg1Of immunoglobulin,20 g/d
R26413 T6163 T32422 arg1Of improved,After
R26629 T13833 T79561 arg1Of and,e.g.
R2970 T25963 T66169 arg1Of corticosteroid,moderate-dose
R31347 T98815 T75376 arg1Of COVID-19,demonstrated
R31644 T49266 T10805 arg2Of laboratory,","
R31769 T65830 T31198 arg2Of patients,included
R33163 T64285 T67888 arg1Of all,of
R34129 T11859 T80531 arg2Of and,decreased
R35046 T64285 T38661 arg1Of all,switching
R36622 T91618 T27562 arg2Of plus,of
R36752 T84435 T6426 arg1Of treatment,plus
R37459 T80531 T13833 arg2Of decreased,and
R38202 T95152 T64168 arg3Of ],[
R39324 T13833 T58632 arg1Of and,","
R4003 T6426 T52543 arg2Of plus,following
R40351 T24326 T59786 arg1Of symptoms,worsening
R40508 T65980 T11859 arg2Of saturation,and
R4076 T13833 T83448 arg1Of and,","
R41260 T60445 T91733 arg1Of immunoglobulin,(
R41521 T64285 T6163 arg1Of all,improved
R41915 T58895 T63732 arg1Of outcomes,paraclinical
R43963 T58895 T87507 arg1Of outcomes,clinical
R45642 T22917 T47400 arg2Of dose,to
R46612 T65830 T55004 arg1Of patients,ten
R46705 T87507 T10805 arg1Of clinical,","
R47040 T26688 T69861 arg1Of methylprednisolone,1600 mg/d
R47106 T67776 T67888 arg2Of patients,of
R47262 T21718 T80531 arg1Of study,decreased
R49635 T13833 T52543 arg1Of and,following
R50003 T25963 T65524 arg1Of corticosteroid,short-term
R50369 T21718 T18993 arg1Of study,The
R50386 T89099 T91733 arg3Of ),(
R52803 T51590 T95692 arg1Of and,","
R53992 T58895 T49266 arg1Of outcomes,laboratory
R56085 T22917 T88178 arg1Of dose,double
R59825 T82872 T91618 arg2Of immunoglobulin,plus
R59919 T24326 T75376 arg2Of symptoms,demonstrated
R62745 T38661 T32422 arg2Of switching,After
R63324 T63732 T51590 arg2Of paraclinical,and
R64025 T22917 T27562 arg1Of dose,of
R66734 T98815 T69048 arg1Of COVID-19,who
R68832 T67776 T16788 arg1Of patients,the
R70976 T25963 T99668 arg1Of corticosteroid,a
R75502 T10263 T91733 arg2Of 10 g/d,(
R76274 T66430 T64168 arg2Of 23,[
R78212 T25963 T44273 arg2Of corticosteroid,with
R79029 T31095 T40148 arg1Of count,lymphocyte
R79224 T58895 T27596 arg2Of outcomes,in
R79540 T60445 T6426 arg2Of immunoglobulin,plus
R79576 T22917 T27854 arg1Of dose,the
R82941 T75851 T54040 arg2Of 80 mg/d,(
R86526 T21718 T31198 arg1Of study,included
R89182 T25963 T54040 arg1Of corticosteroid,(
R92060 T6163 T27596 arg1Of improved,in
R92577 T3471 T11859 arg1Of ratio,and
R92905 T31198 T13700 arg1Of included,","
R95496 T75851 T15835 arg1Of 80 mg/d,methylprednisolone
R9661 T98815 T56952 arg2Of COVID-19,with
R96957 T26688 T91618 arg1Of methylprednisolone,plus
R97543 T38661 T47400 arg1Of switching,to
R99800 T55858 T54040 arg3Of ),(